Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing

Mutations in the serine/threonine kinase BRAF are found in more than 60% of melanomas. The most prevalent melanoma mutation is BRAF(V600E), which constitutively activates downstream MAPK signaling. Vemurafenib is a potent RAF kinase inhibitor with remarkable clinical activity in BRAF(V600E)-positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Salton, Maayan, Kasprzak, Wojciech K., Voss, Ty, Shapiro, Bruce A., Poulikakos, Poulikos I., Misteli, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435825/
https://www.ncbi.nlm.nih.gov/pubmed/25971842
http://dx.doi.org/10.1038/ncomms8103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435825/
https://www.ncbi.nlm.nih.gov/pubmed/25971842
http://dx.doi.org/10.1038/ncomms8103

Ejemplares similares